Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Verrica Pharmaceuticals Inc. (VRCA)
|
Add to portfolio |
|
|
|
| Price: |
$9.44
| | Metrics |
| OS: |
42.1
|
M
| |
-42
|
% ROE
|
| Market cap: |
$397
|
M
| |
|
|
|
Net cash:
|
$205
|
M
| |
$4.88
|
per share
|
|
EV:
|
$192
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($29.9)
|
M
| |
|
|
|
EBIT
|
($29.9)
|
M
| |
|
|
| EPS |
($0.56)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 9.0 | 12.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.7 |
| Revenue growth | -24.7% | | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.9 |
| Gross profit | 9.0 | 12.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 |
| Gross margin | 100.0% | 100.0% | | | | | -11.9% |
| Selling, general and administrative | 30.3 | 42.9 | 40.2 | | | | |
| Research and development | | | | 15.4 | 12.8 | 3.7 | |
| General and administrative | | | | 14.6 | 9.1 | 0.7 | 0.2 |
| EBIT | -27.7 | -39.3 | -45.2 | -30.1 | -21.9 | -4.5 | -1.9 |
| EBIT margin | -306.4% | -327.1% | | | | | -111.9% |
| Pre-tax income | -24.5 | -35.1 | -42.7 | -28.2 | -20.6 | -4.5 | -1.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -24.5 | -35.1 | -42.7 | -28.2 | -20.6 | -9.8 | 0.0 |
| Net margin | -271.1% | -292.3% | | | | | -0.1% |
| |
| Diluted EPS | ($0.72) | ($1.30) | ($1.71) | ($1.13) | ($1.41) | ($3.42) | ($0.52) |
| Shares outstanding (diluted) | 34.2 | 27.0 | 25.0 | 24.9 | 14.7 | 2.9 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|